Last reviewed · How we verify
NCT05321212: PEMBREIZH
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
trial in Carcinoma, Non-Small-Cell Lung in 108 participants. Completed in 2 March 2019.
2 January 2019
Quick facts
| Lead sponsor | University Hospital, Brest |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 108 |
| Start date | 2 January 2019 |
| Primary completion | 2 January 2019 |
| Estimated completion | 2 March 2019 |
| Sites | 2 locations across France |
Conditions studied
- Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
- Immunotherapy — all drugs for Immunotherapy →
Sponsor
University Hospital, Brest
Who can join
18 and older, any sex, with Carcinoma, Non-Small-Cell Lung or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05321212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carcinoma, Non-Small-Cell Lung
Currently open trials in the same condition.
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
- NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
- NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
- NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
- NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting
Other University Hospital, Brest trials
Trials by the same sponsor.
- NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
- NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
- NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
- NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
- NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05321212 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
- Last refreshed: 11 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05321212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing